Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
Beijing Biotech
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07589543CT.gov Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer | — | Recruiting | — | — | — |
NCT07617753CT.gov Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 | — | Recruiting | — | — | — |
NCT06483048CT.gov MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer | — | Recruiting | — | — | — |
NCT06305299CT.gov Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells | — | Recruiting | — | — | — |
NCT05714306CT.gov PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma | — | Withdrawn | — | — | — |
NCT05225363CT.gov Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer | — | Recruiting | — | — | — |
NCT05075993CT.gov Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04670068CT.gov Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian | — | Active Not Recruiting | — | — | — |
NCT04282044CT.gov Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT02948101CT.gov PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Withdrawn | — | — | — |
Show 15 more trialsShow fewer
NCT03610490CT.gov Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | — | Terminated | — | — | — |
NCT03318900CT.gov T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | — | Completed | — | — | — |
NCT03449108CT.gov LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | — | Active Not Recruiting | — | — | — |
NCT03017131CT.gov Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Active Not Recruiting | — | — | — |
NCT02650986CT.gov Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 | — | Active Not Recruiting | — | — | — |
NCT02853318CT.gov Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT02785250CT.gov Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT03332576CT.gov Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | — | Completed | — | — | — |
NCT01606241CT.gov Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | — | Completed | — | — | — |
NCT01312376CT.gov Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer | — | Terminated | — | — | — |
NCT01175772CT.gov Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy | — | Terminated | — | — | — |
NCT00551265CT.gov Oregovomab With or Without Cyclophosphamide in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Responded to Second-Line Chemotherapy | — | Withdrawn | — | — | — |
NCT00538031CT.gov Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | — | Completed | — | — | — |
NCT00228358CT.gov Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Cyclophosphamide (this asset) | Beijing Biotech | P2 | BB · 67 |
| Trabectedin | AGO Research GmbH | P4 | BBB |
| Mirvetuximab Soravtansine | AstraZeneca | P3 | BBB |
| Carboplatin | University of Washington | P3 | BB |
| Olaparib | Imunon | P4 | BB |
| Irinotecan | OHSU Knight Cancer Institute | P2 | BB |
| Palbociclib | University Medical Center Groningen | P4 | BB |
| Durvalumab | AGO Research GmbH | P2 | BB |
| Lenvatinib | University Medical Center Groningen | P4 | BB |
+42 more in the Ovarian Carcinoma cohort
Other indications for Cyclophosphamide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| Mycosis Fungoides | — | P4 | BBB · 78 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Cyclophosphamide in Ovarian Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/cyclophosphamide-ovarian-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →